EUVIMEDEUVIMED entdecken
Crossref

EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer

Mali Barbi, Divya Bhana, Veena S. John

AME Clinical Trials Review · 2026-06 · 4 · 25-25

DOI: 10.21037/actr-25-109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Mali Barbi und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Barbi, M., Bhana, D., & John, V. S. (2026). EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer. AME Clinical Trials Review, 4, 25-25. https://doi.org/10.21037/actr-25-109

Vancouver

Barbi M, Bhana D, John VS. EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer. AME Clinical Trials Review. 2026;4:25-25. doi:10.21037/actr-25-109

BibTeX
@article{Barbi2026,
  author = {Barbi, Mali and Bhana, Divya and John, Veena S.},
  title = {EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer},
  journal = {AME Clinical Trials Review},
  year = {2026},
  volume = {4},
  pages = {25--25},
  doi = {10.21037/actr-25-109}
}
Kostenlos starten →